Olaf Witt

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 217 publications

PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma.

PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma.

Journal: The New England journal of medicine
Published: August 12, 2026

Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

Journal: JCO precision oncology
Published: July 15, 2026

Correction: Paediatric Phase I/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis.

Correction: Paediatric Phase I/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis.

Journal: Pharmaceutical medicine
Published: June 18, 2026

Switching Tracks: Activity of Entrectinib After Progression While on Larotrectinib in Neurotrophin Receptor Tyrosine Kinase-Fused Pediatric High-Grade CNS Tumors.

Switching Tracks: Activity of Entrectinib After Progression While on Larotrectinib in Neurotrophin Receptor Tyrosine Kinase-Fused Pediatric High-Grade CNS Tumors.

Journal: JCO precision oncology
Published: May 14, 2026

Paediatric Phase I/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis.

Paediatric Phase I/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis.

Journal: Pharmaceutical medicine
Published: March 24, 2026

Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience.

Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience.

Journal: Genome medicine
Published: February 17, 2026

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Journal: The Journal of clinical investigation
Published: February 12, 2026

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Journal: Cancer research
Published: November 19, 2025

Response to letter from Dr. Avery.

Response to letter from Dr. Avery.

Journal: Neuro-oncology
Published: November 12, 2025

Integration and validation of complementary ex vivo assays for functional precision oncology.

Integration and validation of complementary ex vivo assays for functional precision oncology.

Journal: NPJ precision oncology
Published: October 30, 2025

Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene.

Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 09, 2025

Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.

Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.

Journal: Nature communications
Published: October 09, 2025
Showing 1-12 of 217

Last Updated: 09/26/2026